← Patent-cliff monitor small molecule BRINSUPRI BRENSOCATIB
Loss of exclusivity February 2040 latest FDA-listed patent expiry
Company Insmed → View the full company profile on CliffBio Drug detail Brand name BRINSUPRI Active ingredient BRENSOCATIB Strength 10MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval August 2025 Marketing status RX
Listed patents Patent Expires Type 12059424 February 2040 product 12201638 March 2039 product 9522894 March 2035 substance 11673871 January 2035 product 11655224 January 2035 product 11655223 January 2035 substance 11655222 January 2035 substance 12054465 January 2035 substance 10669245 January 2035 substance 10287258 January 2035 substance 9815805 January 2035 use U-4257 11655221 January 2035 product 11814359 January 2035 substance 11773069 January 2035 product
Regulatory exclusivity Code Expires NCE August 2030
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.